AURIS MEDICAL HOLDING news, videos and press releases - Page 2
For more news please use our advanced search feature.
AURIS MEDICAL HOLDING - More news...
AURIS MEDICAL HOLDING - More news...
- Auris Medical Announces Positive Top-Line Data from AM-201 Phase 1b Study in Antipsychotic-Induced Weight Gain and Provides Update on TRAVERS Phase 2 Study
- Auris Medical Provides Business Update and Reports Second Half and Full Year 2019 Financial Results
- Auris Medical Provides Update on Intranasal Betahistine Development Program
- Auris Medical Provides Update on Ongoing Clinical Trials with Intranasal Betahistine
- Auris Medical Highlights Publication of Study Results Demonstrating Betahistine’s Antiepileptogenic and Anticonvulsant Activity in Murine Model
- Auris Medical Announces Notice of Allowance for European Patent Application
- Auris Medical Holding Ltd. - EARS Stock Chart Technical Analysis for 12-30-2019
- Auris Medical Announces Formation of New Subsidiary for Development Projects in Tinnitus and Hearing Loss
- Auris Medical Announces Positive Interim Results from AM-201 Phase 1b Study in Antipsychotic-Induced Weight Gain
- Auris Medical Receives FDA and EMA Guidance for Keyzilen® Late-Stage Clinical Development Program
- Auris Medical Announces Notices of Allowance for U.S. and European Patent Applications Covering Intranasal Betahistine
- Auris Medical Announces Appointment of New Chief Financial Officer
- Auris Medical Announces Formation of Scientific Advisory Board for Tinnitus Programs
- Auris Medical Provides Business Update and Reports First Half 2019 Financial Results
- Auris Medical Announces Randomization of First Patient in AM-125 Phase 2 Trial in Acute Vertigo
- Auris Medical Holding Ltd. - EARS Stock Chart Technical Analysis for 06-05-2019
- Auris Medical Holding Ltd Provides Corporate Update
- Auris Medical Holding Ltd Regains Compliance with Nasdaq Minimum Bid Price Rule
- Auris Medical Announces Closing of Public Offering of Common Shares
- Auris Medical Announces Closing of Two US Patent Acquisitions Related to the Use of Betahistine for the Treatment of Depression and ADHD
- Auris Medical Holding Ltd.:
- Auris Medical Reaches Midpoint for Enrollment in AM-201 Phase 1b Proof-of-Concept Study in Antipsychotic-Induced Weight Gain
- Auris Medical Announces Reverse Stock Split
- Auris Medical Provides Update on Tinnitus Drug Development Strategy
- Auris Medical Receives Positive Nasdaq Listing Determination
- Auris Medical Announces Randomization of First Dose Cohort in AM-201 Phase 1b Proof-of-Concept Study
- Auris Medical Announces 20-F Filing
- Auris Medical Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results
- Auris Medical Announces Publication of AM-111 Phase 3 Results in Peer-Reviewed Scientific Journal
- Auris Medical to Report Fourth Quarter and Full Year 2018 Financial Results and Provide Business Update on Thursday, March 14, 2019